top of page

DRUG DISCOVERY PIPELINE

Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, malaria, dengue, leishmania, bacterial infections, COVID-19 and RSV, spanning over early-stage discovery to late-stage clinical trials. Click here for FNDR's areas of research focus, our publications and information about our research programs.

Hit to Lead
Lead Optimization
IND Enabling Studies
Repurposed Drugs
Phase 1
Phase 2
Phase 3

TUBERCULOSIS

NONTUBERCULOUS MYCOBACTERIA

BACTERIAL INFECTIONS

FUNGAL INFECTIONS

MALARIA

LEISHMANIA

COVID-19

RESPIRATORY SYNCYTIAL VIRUS

DENGUE

CONTRACT SERVICES

FNDR performs various preclinical in vitro and animal studies for BSL-2 and BSL-3 bacterial, fungal and viral pathogens under a fee-for-service mode to test therapeutics, vaccines, and other items. Click here for more information.

Therapeutics Testing 
Vaccines Testing

Virucidal Assays

In vitro Models
Animal Models

ACHIEVEMENTS

1

Drug in Clinical Development

30+

Ongoing Innovation Projects on Infectious Disease Drug Discovery and Platform Technologies.

4

Repurposed drugs under development

100+

Contract Research Projects Completed

13

New Drugs in Preclinical Development

50+

Research and Development Partners

LATEST NEWS

Scientists from Spain and India Lead an International Project to Develop New Antibiotics Against Gram-Negative Bacteria

8 September 2022

Foundation for Neglected Disease Research (FNDR), ABAC Therapeutics, together with the artificial intelligence (AI) company, Peptris, and with scientific support from Medicines for Malaria Venture (MMV), will collaborate in an international project to optimize a new chemical structure that has shown effectiveness against Gram-negative bacteria, the greatest current threat to public health. In recent decades, there has been a significant increase in the incidence of infections caused by the Gram-negative bacteria known as “the four killers”: Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae. The team of researchers intends to identify and optimise molecules that could be progressed to clinical studies within the next two years.

bottom of page